Strategic Partnership Opportunity: Bochéry & Dallah Healthcare

[Virtual Presenter] We are presenting opportunities for strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia..

[Audio] Our commitment to innovation has led us to develop cutting-edge products that harness the power of nanotechnology and biotechnology. We have been revolutionizing the field since 2007 with our premium skincare brand, Bochéry Lab Esthétique. Our unique approach involves encapsulating our advanced active ingredients within liposomes, allowing for optimal skin penetration and delivering the best possible results. This is our promise to our clients, and it is what drives our vision forward..

[Audio] Our premium dermal cosmetic products have been carefully crafted to provide exceptional results for our customers. With a focus on quality and innovation, we strive to stay ahead of the curve in the industry. By using only the finest ingredients and cutting-edge technology, we ensure that every product meets the highest standards of excellence. Whether it's enhancing skin tone, reducing fine lines and wrinkles, or providing long-lasting hydration, our products are designed to deliver real results..

[Audio] Our dermal fillers offer a range of treatments designed to enhance beauty and restore vitality. With our expertise, we can help you re-treat and renew your skin, addressing concerns such as fine lines, wrinkles, and loss of facial volume. Our dermal fillers are carefully selected to provide optimal results, ensuring a natural-looking appearance that complements your unique features. Whether you're looking to revitalize your complexion or address specific areas of concern, our team is dedicated to helping you achieve your aesthetic goals.

[Audio] In our fast-paced world, it can be challenging to maintain a balanced diet and get all the essential nutrients our body needs. This is where multivitamins come in. They are a convenient and effective way to supplement our diet and ensure we are getting all the necessary vitamins and minerals. At IEEE Bochéry LAB ESTHÉTIQUE, we understand the importance of incorporating multivitamins into our daily routine. Our experts have carefully formulated a special blend of multivitamins that are specifically designed to nourish and enhance the beauty of your skin. These multivitamins contain powerful antioxidants and essential vitamins that work together to protect your skin from environmental damage and keep it looking youthful and radiant. But it's not just about external beauty. Multivitamins also play a crucial role in our overall health and well-being. They boost our immune system, support healthy brain function, and help prevent chronic diseases. In fact, studies have shown that individuals who take multivitamins regularly are less likely to experience deficiencies and have a lower risk of certain health conditions. So don't underestimate the power of multivitamins. Take the first step towards a healthier and more beautiful you by incorporating our specially formulated multivitamins into your daily routine. With IEEE Bochéry LAB ESTHÉTIQUE, you can achieve optimal skin health and overall wellness..

[Audio] LYSASPIR@ is a pharmaceutical product containing LYSINE ACETYLSALICYLATE, an injectable medication used for its analgesic and anti-inflammatory properties. This medication provides relief from pain while being safe for use. The product comes in vial form, with six vials and ampules of solvent included. The manufacturer's name is Bechéyy, and the product has been assigned the registration number 5120765..

[Audio] The proposed financial proposal for the strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia includes a partnership structure where Bochéry will hold a 40% to 50% share, while Dallah Healthcare will hold the remaining share. The duration of the partnership is initially set for three years, with predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering or a buyout option where Dallah Healthcare can acquire Bochéry's share. The calculation determines the target number of patients to be served by the partnership. The conclusion emphasizes the mutual benefits of the partnership and outlines the next steps for launching in KSA, including approval of partnership terms, regulatory filings, market-specific product trials, deployment of joint marketing campaigns, and setup of distribution channels through Dallah's healthcare network..

[image]. No photo description available.. London.

[Audio] Bochéry and Dallah Healthcare are entering into a strategic partnership, and it is crucial to recognize the significance of each entity involved. The logos or brand marks displayed represent the distinct identities, values, and missions of each party. By acknowledging these differences, we can better comprehend the unique strengths and contributions they bring to our collaborative efforts. This understanding will enable us to work more efficiently together, combining the expertise and resources of each partner to achieve our shared objectives..

[Audio] Assuming we capture 0.5% of the skincare market in key regions, our estimated annual sales would be substantial. The Middle East would generate between $15 million and $20 million annually, driven by the region's large and growing population. In Europe, we anticipate generating around $8 million to $10 million annually, while in Canada and the UK, we expect to reach $5 million to $7 million annually. Overall, our total estimated annual sales would range from $28 million to $37 million..

CARING FOOT SAVING LIFE. Innovation way to keep diabetic foot on the way Unique treatment for the diabetic foot ulcers systemically and topically in the world..

[Audio] At Bochéry LAB ESTHÉTIQUE, we recognize the difficulties faced by diabetic patients suffering from foot ulcers. Our response has been to develop an advanced, patented treatment product specifically designed to accelerate healing and mitigate potential complications, both locally and systemically..

[Audio] LYTONIC ™ is the most effective medication for treating the condition, as research indicates. The healing process is enhanced by improving blood circulation in the ulcer, with no side effects reported. This innovative nano-biotechnological product comes in two pharmaceutical forms: gel and capsules, which allow it to work both topically and systemically..

[Audio] LYTONIC Plus™ capsules are a powerful oral supplement designed to support lymphatic and blood microcirculation, cells oxygenation, promote antioxidant action, and enhance the body's natural healing processes. These benefits are vital to treat various types of skin ulcers, including diabetic foot ulcers, postoperative ulcers, burns, and bedsores..

[Audio] LYTONIC Gel ™ works through its antioxidant properties, improving blood circulation and strengthening the lymphatic system. This mechanism allows for the removal of dead tissue in the affected area. Additionally, it hydrates and revitalizes damaged skin cells, reduces inflammation, and promotes granulation and reepithelization at the wound site. Furthermore, it enhances lymphatic, blood flow, and oxygenation of damaged tissues, providing a soothing effect and anti-inflammatory action..

[Audio] Our treatment approach addresses both systemic and localized factors of Diabetic Foot Ulcer, providing comprehensive care through internal and external applications. This integrated therapy combines the benefits of capsules, which improve lymphatic and blood microcirculation, reducing internal inflammation, with the soothing, hydrating, and protective properties of our gel. By working together, these components accelerate healing, minimize the risk of infection, and promote overall foot health. The synergistic effects of this combined treatment enable effective and efficient recovery from Diabetic Foot Ulcer..

[image] ooocts LYTONIC LYTONIC • PLUS/ CGM system Gluco-Sensor 24h Gluco Sensor 24h from Bochéry V.OIIJ BOCPQÜ Clnco 260201. sqp Bochéry Bbd,péi.ix.

[Audio] Bochéry and Dallah Healthcare are partnering to introduce three products, namely LYTONIC Plus & Gel, Wound Care Plaster, and Gluco-Sensor 24h, to the KSA market. The partnership aims to capitalize on the growing demand for healthcare solutions in the region by combining Bochéry's advanced technology with Dallah Healthcare's expertise. This collaboration is expected to yield mutually beneficial results, providing top-notch healthcare services to the people of KSA..

[Audio] We envision a future where our strategic partnership with Dallah Healthcare enables us to bring cutting-edge diabetic care solutions to the Kingdom of Saudi Arabia. By combining our expertise and resources, we aim to provide innovative treatments and products that meet the unique needs of the KSA market. This collaboration will not only benefit patients but also drive growth and development in the pharmaceutical industry within the region. Additionally, we are committed to contributing a pharmaceutical production facility in KSA, further solidifying our commitment to this strategic partnership.

[Audio] The population of Saudi Arabia has been consistently growing over the years, reaching approximately 34 million people as of 2024. This growth can be attributed to various factors, including advancements in healthcare, a younger demographic structure, and the influx of foreign workers drawn by the country's expanding economic opportunities under Saudi Vision 2030.

[Audio] Diabetes affects more than 18 percent of the Saudi Arabian population, which amounts to approximately seven million individuals. The estimated prevalence of diabetic foot ulcers ranges from 15 to 25 percent of these patients, corresponding to a minimum of nearly one million cases and a maximum of almost one and a half million cases. These statistics emphasize the necessity for effective prevention and treatment strategies to reduce the impact of diabetes on those affected..

[Audio] Diabetic Foot Ulcers (DFU) and Amputation in Saudi Arabia are analyzed in terms of risks, amputation rates, and future prevalence from 2024 to 2029. The complications of diabetes, including DFU, can lead to amputation if not properly managed. In Saudi Arabia, the prevalence of DFU and amputation is increasing, affecting the healthcare system and quality of life for patients. Factors contributing to DFU include age, gender, type of diabetes, and access to healthcare. Amputation rates in Saudi Arabia are concerning, with many diabetic patients facing the risk of losing a limb, impacting their physical and mental well-being. The prevalence of DFU and amputation is expected to rise in the coming years, emphasizing the need for effective prevention and management strategies..

[Audio] Diabetic Foot Ulcers pose significant risks to patients with diabetes. The main risk factors include neuropathy, which causes loss of sensation in the feet, making it difficult for patients to detect injuries or discomfort. Poor glycemic control also increases the risk of developing DFUs, as does peripheral arterial disease, which reduces blood flow to the extremities. Furthermore, a history of previous foot ulcers significantly raises the likelihood of future occurrences. These risk factors have a profound impact on mortality rates, with patients suffering from DFUs experiencing a mortality rate nearly twice that of those without DFUs. Moreover, amputations, often a consequence of DFUs, lead to even higher mortality rates, reaching as high as 32.2%..

[Audio] In Saudi Arabia, it's estimated that between 5% to 15% of diabetic patients with diabetic foot ulcers may require amputations. This translates to over 3000 diabetic-related amputations occurring annually. Furthermore, our data shows that amputation and mortality rates are significantly higher among males, ranging from 76% to 78%..

[Audio] According to our estimates, by 2024, approximately 7.0 million individuals in Saudi Arabia will have diabetes. This number is expected to rise proportionally, reflecting the growing trend of diabetic foot ulcers, or DFUs. Looking ahead to 2029, we forecast that the prevalence of diabetes will reach 8 million, accompanied by an estimated 20% increase in amputations due to population growth and aging. These statistics underscore the importance of proactive measures to address this critical public health issue..

[Audio] Risks associated with diabetic foot include ulcers and wounds, bacterial infections, amputation, psychological and social impact, and high healthcare costs. These risks can have severe consequences if left untreated or poorly managed..

[Audio] The estimated healthcare costs for diabetic foot in Saudi Arabia are substantial. The annual treatment cost per patient ranges between seventy thousand Saudi riyals and one hundred twenty thousand Saudi riyals. This translates to a total annual cost for all patients of approximately seventy-five billion Saudi riyals, assuming an average of one million five hundred thousand patients..

[Audio] We propose a strategic partnership between Bochéry and Dallah Healthcare in Saudi Arabia. The financial proposal outlines the terms of the partnership, including the structure, duration, and exit strategy options. According to the calculation, our target is to serve patients with diabetic foot ulcers (DFU). We plan to achieve this by establishing a joint venture with a 40% to 50% share held by Bochéry and the remaining share held by Dallah Healthcare. The initial term of the partnership will be three years, during which we will work towards predefined business goals. After the initial term, there are two exit strategy options available: public listing through an initial public offering (IPO), where the company sells shares of its stock to the public on a stock exchange; or a buyout option, where Dallah Healthcare acquires Bochéry's share..

[Audio] Prevention is crucial in managing diabetic foot ulcers. Educating the public and at-risk individuals through health awareness programs can prevent the onset of these complications. Additionally, ensuring better management and monitoring of diabetic patients through improved foot care can significantly reduce the risk of developing mild cases. This proactive approach will ultimately prevent the escalation of the disease, reducing the need for costly treatments and hospitalizations..

[Audio] In Saudi Arabia, there are approximately 500 government and private hospitals providing treatment and care for diabetic foot patients. More than 50 specialized centers focus on treating and managing diabetes and diabetic foot, managed by the Ministry of Health or the private sector. Many hospitals also have specialized units or departments for diabetic foot care, particularly in major hospitals like National Guard hospitals, King Faisal Specialist Hospital, Dallah Hospital, and Dr. Sulaiman Al Habib Hospital. Hundreds of outpatient clinics offer diabetic foot care services, including primary healthcare centers under the Ministry of Health. Notable facilities in this field include King Faisal Specialist Hospital & Research Center, National Guard Health Affairs Hospitals, Dallah Hospital Group, Dr. Sulaiman Al Habib Hospitals, and Diabetes Centers affiliated with the Ministry of Health across various regions..

[Audio] The pharmaceutical market in Saudi Arabia has seen significant growth in recent years, and it is estimated to be over USD 6 billion. Oral medications are the most commonly prescribed treatment for diabetes in Saudi Arabia, but there is an increasing demand for insulin and other injectable treatments. Understanding market trends and consumer preferences is crucial for effective marketing and developing tailored strategies that can improve diabetes care in Saudi Arabia..

[Audio] The current market value of pharmaceuticals in Saudi Arabia was SAR 44 billion, which is equivalent to USD 12 billion, in 2022. This figure is expected to rise to SAR 57 billion, or USD 15 billion, by 2027, representing a CAGR of 5.2%..

[Audio] We will partner with reputable pharmaceutical companies such as Jamjoom Pharma, Avalon Pharma, Tabuk Pharmaceuticals, and SPIMACO to provide high-quality treatment options for our patients. Our focus will be on topical treatments only, ensuring the most effective and efficient care for those we serve..

[Audio] The key players in the KSA market are notable competitors across various categories. Johnson & Johnson, Smith & Nephew, and Mölnlycke Health Care offer patch solutions in the area of Diabetic Foot Ulcer care. Abbott's Freestyle Libre, Medtronic's Guardian, and Dexcom provide Continuous Glucose Monitoring Systems. 3M Healthcare, Smith & Nephew, and regional distributors supply wound care plasters. These competitors shape the market landscape..

[Audio] Each product line requires a significant upfront investment, including regulatory approvals and marketing efforts. This investment is crucial for establishing a strong foundation for our partnership. We estimate that this initial investment will amount to two million dollars. With this investment, we can ensure that our products meet the necessary standards and regulations, and that we have a solid plan in place for promoting them to the market..

[Audio] The partnership between Bochéry and Dallah Healthcare offers numerous benefits for both parties by combining our expertise and resources to bring innovative products and services to the Saudi Arabian market, improving the lives of patients and enhancing the reputation of our companies. To launch our partnership in KSA, we need to approve the partnership terms, ensuring that all parties understand their roles and responsibilities, which involves regulatory filings and market-specific product trials to ensure compliance with local laws and regulations. Next, we will deploy joint marketing campaigns to raise awareness about our partnership and promote our products and services, setting up distribution channels through Dallah's extensive healthcare network, making it easier for patients to access our offerings. By working together, we can achieve great things and create a lasting impact in the healthcare industry..

[Audio] The calculation process for determining our target to serve DFU patients involves defining the target audience, gathering relevant data and information, analyzing the information to identify patterns and trends, setting a realistic and achievable target based on the analysis, and continuously reviewing and adjusting the target as needed..

[Audio] Bochéry and Dallah Healthcare propose a financial plan for their strategic partnership in Saudi Arabia. The plan involves an initial investment of $2 million for establishing a state-of-the-art facility, hiring and training staff, and marketing services. The projected revenue shows a steady increase in demand for aesthetic services, driven by growing awareness and interest among the population. The proposal outlines costs and profits for each year, considering potential operational challenges and market fluctuations. The partnership aims to achieve a significant return on investment within the first three years and contribute to the growth and development of the aesthetic industry in Saudi Arabia..

[Audio] The proposed terms outline the structure and duration of our partnership. Bochéry will retain a significant stake in the venture, holding between 40% to 50% of the shares. The remaining shares will be held by Dallah Healthcare. This partnership structure ensures both parties have a vested interest in the success of our joint endeavor. The duration of this partnership has been set at three years, during which we will work together to achieve specific business objectives. Upon completion of the initial term, we have outlined two exit strategy options. We can explore a public listing through an initial public offering, allowing us to sell shares of our stock to the public on a stock exchange. Alternatively, Dallah Healthcare may choose to acquire Bochéry's share, solidifying their position within the partnership..

[Audio] The references used in this report come from reputable sources. The Saudi Health Council's annual diabetes reports from 2024 provide valuable information on the current state of diabetes in Saudi Arabia. The World Health Organization's global diabetes data from 2023 gives us insight into the global picture of diabetes. The International Journal of Diabetes Research, published in 2024, is dedicated to publishing research on diabetes and its related topics. These sources have been carefully selected to ensure the accuracy and reliability of the information presented in this report..

[Audio] The presentation has concluded, and I would like to express my sincere gratitude to everyone who attended for their attention. Our exploration of the significance of shifting the focus on diabetic foot ulcer treatment and wound care in Saudi Arabia has highlighted the potential for a substantial impact on the region's healthcare future. Once more, thank you for your consideration, and I wish you all the best in your efforts to enhance the lives of those affected by diabetes..